AXL and adrenal cortex carcinoma: Here, to our knowledge, we describe the first patient with ACC treated with AXL-targeted therapy (BA3011) as part of a phase I study (ClinicalTrials.gov identifier: NCT03425279), after identification of her ACC-II disease type.